Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial
Institute of Cancer Research · Royal Marsden NHS Foundation Trust · +11 more institutions
Indexed incrossrefpubmed
Abstract
No abstract available for this paper.
Citation impact
3,280
total citations
- FWCI
- 169.80
- Percentile
- 100%
- References
- 17
Citations per year
Authors
13- JSJohann S. de BonoCorresponding
Institute of Cancer Research, Royal Marsden NHS Foundation Trust
- SOStéphane Oudard
Hôpital Européen, Hôpital Européen Georges-Pompidou
- MÖMustafa Özgüroğlu
Istanbul University
- SHSteinbjørn Hansen
Odense University Hospital
- JMJean-Pascal Machiels
Cliniques Universitaires Saint-Luc, UCLouvain
Topics & keywords
Topics
Keywords
- Cabazitaxel
- Mitoxantrone
- Docetaxel
- Medicine
- Prostate cancer
- Prednisone
- Internal medicine
- Oncology
UN Sustainable Development Goals
- Good health and well-being
No related works found for this paper.